Laboratorios Reig Jofre, the pharmaceutical company listed on the Spanish stock exchange and a member of CataloniaBio & HealthTech, has received a visit from the President of the Generalitat de Catalunya, Pere Aragonès, at its newstate-of-the-art industrial plant for injectables for hospital use. The event was also attended by the President and the CEO of Reig Jofre, Isabel Reig and Ignasi Biosca, and the Mayor of Sant Joan Despí, Belén García.

The President of the Generalitat, Pere Aragonès, emphasized that "Catalonia can make a contribution to Europe in the pharmaceutical field, in the same way as it can in other areas such as energy or technology". He cited the pharmaceutical company Reig Jofre as an example, for its "commitment to continue investing to improve its technological and productive capacity."

The president made these statements after visiting the Reig Jofre facilities in Sant Joan Despí, one of the most modern in Europe, equipped with the latest technology. The company's board of directors approved an ambitious investment plan for the construction of a new plant, the first stone of which was laid in 2019. A technologically advanced plant focused on meeting the demand for injectable drugs, developing new markets internationally and increasing manufacturing services to third parties. The new facilities also increase energy and production efficiency, triple the existing capacity to 45 million freeze-dried vials, from the initial 15 million vials, and could produce up to 50 million a year with liquid solution, additionally.

In 2021,additional investments were made to technologically adapt the plant to the production of any type of vaccine (messenger RNA, viral vector or protein) and other biological drugs. The total investment exceeded 40 million euros.

Reig Jofre stands at € 236 million in sales and EBITTA of € 27.3 million in 2021. It has subsidiaries in 8 countries (Spain, France, Portugal, Belgium, Sweden, theUnited Kingdom, Poland and Singapore) and 155 business partners in more than 70 countries.